Physician profile
Dain E Vines
NPI 1306959614
$2,428.65
in general payments reported to CMS, 2019-2025
27 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $475 · 2021: $877 · 2022: $199 · 2023: $107 · 2024: $155 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $270.40 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $246.68 | 2019-2021 | |
| Glaxosmithkline, LLC. | $244.26 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $224.19 | 2020-2022 | |
| Amarin Pharma, INC. | $186.93 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.96 | 2019-2022 | |
| Novo Nordisk INC | $166.78 | 2019-2024 | Wegovy |
| Abbvie INC. | $148.46 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $125.02 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $78.73 | 2021 | |
| Pfizer INC. | $72.51 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.27 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.02 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $50.99 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $47.27 | 2023-2025 | Quviviq, Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $32.89 | 2021 | |
| Arbor Pharmaceuticals, INC. | $31.32 | 2019-2020 | |
| Shire North American Group INC | $28.86 | 2019 | |
| Lundbeck LLC | $25.76 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2025 | |
| Gilead Sciences, INC. | $22.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.88 | 2019 | |
| Medtronic Minimed, INC. | $19.80 | 2020 | |
| Exact Sciences Corporation | $16.82 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.20 | 2019 | |
| Merck Sharp & Dohme LLC | $12.74 | 2023 | Verquvo, Belsomra |
| Cranial Technologies, INC | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dain Vines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.